Mode
Text Size
Log in / Sign up

Synchronous bone-metastatic prostate cancer incidence 6% with median survival of 43 months in Chinese cohortWhat happens when prostate cancer spreads to bones at diagnosis?

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note prognostic factors in a high-risk Chinese SBM-HSPC cohort: HVD linked to worse survival, age 60-74 to better.

A retrospective cohort study analyzed patients diagnosed with synchronous bone-metastatic hormone-sensitive prostate cancer (SBM-HSPC) at a major tertiary center in China between 2017 and 2023. The study aimed to describe the incidence, patient characteristics, and prognostic factors for overall survival in this population. The sample size and median follow-up duration were not reported.

The analysis found the incidence of SBM-HSPC among prostate cancer patients was 6.09%. The cohort was characterized by high-risk features: 93.1% had a Gleason score of 8 or higher, and 83.7% were classified as having high-volume disease (HVD). The median overall survival for the cohort was 43 months. In a multivariate analysis, HVD was an independent risk factor for worse survival, with a hazard ratio of 2.37 (P = 0.012). Conversely, being aged 60-74 years was associated with better survival compared to other age groups, with a hazard ratio of 0.52 (P = 0.040).

Safety and tolerability data for treatments, including novel hormonal therapies, were not reported. Key limitations include the retrospective, single-center design from China, which limits generalizability to other healthcare settings and populations. The cohort represents a particularly high-risk group, which may not reflect the broader SBM-HSPC population. The study used landmark analysis to mitigate immortal time bias, but the findings remain observational associations, not proof of causation. The practice relevance is restrained; the data provide a prognostic snapshot for a specific high-risk subgroup in a Chinese setting but do not guide specific therapeutic interventions.

Imagine being diagnosed with prostate cancer and learning it has already spread to your bones. This is the reality for a small but significant group of men. A study looking back at patient records from a major hospital in China found that about 6% of men with prostate cancer had this 'synchronous' bone spread at the time of their diagnosis. The men in this study tended to have aggressive disease—over 90% had high-grade tumors, and over 80% had cancer in many bone sites.

For these men, the median overall survival was about 43 months from diagnosis. The research also identified key factors linked to survival. Having high-volume disease—meaning cancer in many bones—was associated with more than double the risk of death compared to having fewer bone metastases. Interestingly, being between 60 and 74 years old was linked to a lower risk of death compared to being younger or older.

It's crucial to understand what this study is and isn't. It's a retrospective look at a specific group of men treated at one center in China, so the findings may not directly translate to all patients everywhere. The men in this study were a high-risk group, which helps explain the survival numbers. The study shows associations—like the link between more bone metastases and worse outcomes—but it cannot prove that one thing causes another. This is a snapshot of a challenging situation, providing a clearer picture of what some men and their doctors face.

What this means for you:
When prostate cancer spreads to bones at diagnosis, survival is often measured in years, not decades.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundThe incidence and prognosis of synchronous bone-metastatic hormone-sensitive prostate cancer (SBM-HSPC) in contemporary China remain unclear. This study aimed to determine its current prevalence, characterize patient profiles, and identify independent prognostic factors.MethodsWe conducted a retrospective cohort study of patients with SBM-HSPC diagnosed at a major tertiary center in China (2017-2023). Demographic, clinicopathological, treatment, and outcome data were analyzed. Overall survival (OS) was evaluated using Kaplan-Meier and Cox regression. A landmark analysis (3- and 6-month) was employed to assess the association between early treatment initiation and OS, mitigating immortal time bias.ResultsThe incidence of SBM-HSPC was 6.09%. The cohort presented with high-risk features: 93.1% had Gleason score ≥8,and 83.7% had high-volume disease (HVD). The median OS was 43 months. Multivariate analysis identified HVD as an independent risk factor (HR = 2.37, P = 0.012) and age 60–74 years as protective (HR = 0.52, P = 0.040) compared to age
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.